Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Congress Wrap: EHA 2025
July 2025
Our wrap-up video captures all the key moments from the European Hematology Association (EHA) Congress 2025, watch now
Read more
3 Jul 2015
SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma
An update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma.
3 Jul 2015
Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL
At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the…
3 Jul 2015
Ongoing studies by the German CLL study group (GCLLSG)
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses…
3 Jul 2015
HELIOS: Phase 3 trial of ibrutinib in previously treated CLL/SLL
At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the…
26 Jun 2015
ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain…
26 Jun 2015
Results of the phase 4 EXELS study of high-risk patients with essential thrombocythemia
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust…
26 Jun 2015
Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…
26 Jun 2015
The crucial roles of GFI1B in platelet development
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…
26 Jun 2015
Pacritinib therapy led to symptom improvement in myelofibrosis
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…
26 Jun 2015
Treatment and outcome of CML patients from the EUTOS population-based registry
The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).
26 Jun 2015
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
26 Jun 2015
Adding elotuzumab to standard treatment for myeloma reduced disease progression
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…
12 May 2015
Dr Keith Stewart chairs a discussion on tumour biology-guided treatment for multiple myeloma
At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas…
12 May 2015
Clinical significance of progenitor cells in multiple myeloma
Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) and Prof Gareth…
17 Feb 2015
Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 3)
Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Andre Goy (John Theurer Cancer Center, Hackensack, NJ) at the 2014 American Society…
17 Feb 2015
ASH 2014: Recent investigational advances in mantle cell lymphoma treatment
Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the…
Loading posts...
« Previous
1
…
6
7
8
9
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View